Abstract: A supported catalyst includes: (1) a catalyst support; and (2) deposits of a catalyst covering the catalyst support, wherein the deposits have an average thickness of about 2 nm or less, and the deposits are spaced apart from one another.

Abstract: Ferromagnetic materials are disclosed that comprise at least one Dirac half metal material. In addition, Dirac half metal materials are disclosed, wherein the material comprises a plurality of massless Dirac electrons. In addition, ferromagnetic materials are disclosed that includes at least one Dirac half metal material, wherein the material comprises a plurality of massless Dirac electrons, wherein the material exhibits 100% spin polarization, and wherein the plurality of electrons exhibit ultrahigh mobility. Spintronic devices and heterostructures are also disclosed that include a Dirac half metal material.

Abstract: Disclosed are steerable needles having a shaft that can be controllably buckled, a steering head positioned at a distal end of the shaft, a transmission for controlling the orientation of the steering head, and a base at the end of the shaft, the base optionally comprising a controller for controlling the transmission. Also disclosed are methods of using the disclosed steerable needles.

Abstract: An acellular, anion-depleted platelet-derived peptide-rich composition comprising proteins, polypeptides and peptides <10 kDa in size, wherein the composition has anti-microbial and/or anti-inflammatory activity is disclosed. The composition can be substantially free of non-active and immunogenic factors. The composition can have a platelet-to-bacteria ratio ?1000:1. The composition can comprise plasma at a range of ?10% to ?50% plasma, optionally about 10% plasma. Methods of using the composition are also disclosed.

Abstract: The disclosure provides an optical probe comprising an optical waveguide attached to a molecular switch that produces an altered optical signal upon binding a target molecule. The disclosure also provides an optical sensor system comprising an optical probe, a light source configured to emit the excitation light to be coupled into the optical waveguide of the optical probe; and a detector.

Abstract: Provided herein are methods for treating, reducing and/or ameliorating symptoms of autism spectrum disorder (ASD) in a subject, where at least one measure of social impairment, anxiety, or repetitive behaviors is treated and/or ameliorated. Aspects include intranasally administering arginine vasopressin (AVP), or an analog of vasopressin, to a subject (e.g., a child between 6 and 12 years of age and having endogenous pre-treatment levels between about 0.045 and about 4.028 pg/mL, where the mean was 1.324 pg/mL). In children having high pre-treatment blood levels of AVP (e.g., about 25% or more above the mean pre-treatment AVP blood levels of the treatment group; or having pre-treatment blood vasopressin levels greater than 1.324 pg/mL), the treatment was enhanced. Because no difference in pre-treatment blood AVP levels was observed between control and ASD subjects, it was surprising that AVP treatment was more effective in subjects having high pre-treatment AVP levels.

Abstract: A nanoparticle delivery system designed for sustained delivery of microRNA-150 (miR-150) to FLT3-overexpressing acute myeloid leukemia (AML) cells, the delivery system comprising poly(amidoamine) (PAMAM) dendrimers complexed with miR-150, wherein at least one dendrimer is surface-functionalized with a ligand specific for FLT3 receptor, and methods for treating AML characterized by FLT3-overexpression are provided.

Abstract: The disclosure provides methods for improved hematopoietic stem cell transplantations, including methods to enhance protection from graft versus host disease while maintaining effective immune responses such as graft versus tumor immune responses. The disclosure provides methods for administering, for example, hematopoietic stem and progenitor cells, regulatory T cells, and conventional T cells, wherein the conventional T cells are administered after the hematopoietic stem and progenitor cells and regulatory T cells. The disclosure also provides methods for administering, for example, hematopoietic stem and progenitor cells, regulatory T cells, and conventional T cells, wherein the regulatory T cells have not been cryopreserved prior to administration.

Abstract: Methods are provided for the isolation and analysis of circular DNA from complex samples, based on the topology of the DNA molecule. A sample comprising DNA species is combined with a chaotropic dense salt solution. A fraction containing the circular DNA of interest is isolated and dialyzed to remove excess salt. In some embodiments salt gradients are generated by ultracentrifugation in the absence of intercalating dyes, e.g. ethidium bromide; and in the absence of protease digestion. The circular DNA thus isolated is substantially pure, e.g. greater than about 75%, greater than about 80%, greater than about 90%, greater than about 95% of DNA in the isolated fraction is comprised of circular DNA.

Abstract: The present disclosure relates to delta-2-tubulin and its use as a biomarker for determining if a subject is at risk of developing peripheral neuropathy or if a subject has developed peripheral neuropathy. The present disclosure further relates to methods for the treatment of peripheral neuropathy in a subject and assays for identifying compounds that can be used to treat and/or prevent peripheral neuropathy.

Abstract: The methods and compositions described herein are directed to regulated synthetic gene expression systems. In particular, the technology described herein relates to compositions, systems and methods for inducible and transient (e.g., reversible) transcriptional repression of a target transcript of interest (GOI). The methods, compositions and systems described herein relate to engineered synthetic transcription factors (synTF) that are activated by an inducer molecule, which induces the transcription of a repressor or gene editing molecule from a synthetic inducible repressor constructs where the antisense repressor (or gene editing molecule) mediates reversible repression of a target transcript of interest (GOI) in the presence of the inducer.

Abstract: The present invention provides a compound having the structure: wherein R1 is —(C2-C12 alkyl), -(alkenyl), -(alkynyl), -(cycloalkyl); R2 is H, halogen, —NO2, —CN, —CF3, —CF2H, —CH2OCH3, —CF2CH3, —CF2OCH3, -(alkyl), -(alkenyl), -(alkynyl), -(cycloalkyl), -(cycloalkylalkyl), -(heteroalkyl), -(heterocycle), -(heterocycloalkyl), -(aryl), -(heteroaryl), -(hydroxyalkyl), -(haloalkyl), -(alkylaryl), —OH, —O-(alkyl), —O-(alkenyl), —O-(alkynyl), —O-(haloalkyl), —O-(aryl), —O-(heteroaryl), —OCF3, SH, —S-(alkyl), —S-(alkenyl), —S-(alkynyl), —S-(aryl), —S-(heteroaryl), —NH2, —NH-(alkyl), —NH-(alkenyl), —NH-(alkynyl), —N-(alkyl)2, NH-(aryl), —NH-(heteroaryl), —CO2H, —CO2-(alkyl), —C(O)—NH2, —C(O)—NH-(alkyl), —C(O)—NH-(aryl), —SO2CH3 or —Si(CH3) 3; R3 is —OCH3, —OCH2CH3, —F or —Cl; and R4 is —OCH3, —OCH2CH3 or —SCH3; wherein when R1 is —CH2CH3, R3 is —OCH3, and R4 is —OCH3, then R2 is other than H, —CH3, —CH2CH3, —CH2CH2CH3, —CH(CH3)2, —CH2CH2CH2CH3, —CH2OH, —CH(OH) CH3, —OH, —OCH2CH3, —OCH2CH2CH3, —OCH(CH3)2, —SCH3,

Abstract: Aspects of various embodiments are directed to sensor apparatuses and methods thereof. An example sensor apparatus includes a capacitor and sensor circuitry. The capacitor includes a first substrate having a first electrode, a second substrate having a second electrode, and a dielectric layer. The dielectric layer has a plurality of apertures arranged in a pattern, the first and second electrode being separated by the dielectric layer and arranged with an overlapping area with respect to one another. The sensor circuitry is coupled to the capacitor and configured and arranged to detect normal and shear forces applied to the sensor apparatus based on changes in capacitance derived from changes in at least one of a distance between the first and second electrodes and the overlapping area of the first and second electrodes.

Abstract: A method and system for multi-object tracking is set forth. Object data for boundaries of a plurality of objects are received. Poisson multi-Bernoulli mixture filtering is performed on the object data to form a filtered set of object data. Ultimately, the filtered set of object data is used to control the operation of the vehicle. Identifiers and probabilities are associated with the objects to reduce the set of object data.

Abstract: A polyacrylamide-based copolymer reduces or prevents aggregation of biologic molecules including proteins, peptides, and nucleic acids, and lipid-based vehicles such as liposomes, lipid nanoparticles, polymerosomes, and micelles, in aqueous formulations at hydrophobic interfaces, thereby increasing the thermal stability of the molecules in the formulation. Methods and compositions comprising the copolymer and a protein or the copolymer and insulin can be used for treating conditions including diabetes.

Abstract: A load modulated balanced amplifier (LMBA) circuit can include an input pad of the LMBA circuit configured to receive an input signal on a semiconductor die. A transformer-based hybrid splitter can be coupled to the input pad and configured to provide a first split input signal and a second split input signal from the input signal. A control power amplifier circuit coupled the first split input signal and a power amplifier circuit coupled to the second split input signal.

Abstract: Disclosed are methods, systems, devices, media, circuits, and other implementations, including a method that includes generating for a code block of a process executing on a controller-based device one or more code block copies defined in a virtual address space of the controller-based device, with the code block of the process being stored in a particular segment of a physical address space of the controller-based device, and with the code block configured to separately map to each of the one or more of the code block copies in the virtual address space. The method further includes processing at least a portion of one of the one or more code block copies defined in the virtual address space when the corresponding code block of the process is to be processed.

Abstract: The presently disclosed subject matter provides a biomimetic organ model, and methods of its production and use. In one exemplary embodiment, the biomimetic organ model can be a multi-layer model including a at least two microchannels and at least one chamber slab with at least one membrane coated with cells disposed between at least one microchannel and the at least one chamber slab. In another exemplary embodiment, the biomimetic organ disease model can be a five-layer model including a first and second microchannel with a membrane-gel layer-membrane coated or encompassing cells disposed between the microchannels. In certain embodiments, at least one device can be coupled to the biomimetic organ model that delivers an agent to at least one microchannel.

Abstract: A method for quantitative magnetic resonance imaging (MRI) includes [800] performing an MRI scan using a conventional pulse sequence to obtain a qualitative MR image; and [802] applying the qualitative MR image as input to a deep convolutional neural network (CNN) to produce a quantitative magnetic resonance (MR) relaxation parametric map. The qualitative MR image is the only image input to the deep neural network to produce the quantitative MR relaxation parametric map. The conventional pulse sequence may be a Spoiled Gradient Echo sequence, a Fast Spin Echo sequence, a Steady-State Free Precession sequence, or other sequence that is commonly used in current clinical practice.

Abstract: Simulated motion of the papillary muscles in a heart simulator is provided that simulates natural motion of the papillary muscles. This improves heart valve simulation. This can be done with a six degree of freedom robotic actuator (e.g., a Stewart platform or the like) appropriately driven by a controller. This can also be done with a robotic actuator that provides constrained motion of its effector by including a mechanical linkage, as long as the resulting simulated papillary muscle motion includes time-varying position and orientation of the papillary muscle.